This is a “mammogram moment” for Alzheimer’s. When Congress enabled Medicare coverage for routine mammograms, screening rates soared and breast cancer deaths dropped significantly. Congress can deliver that same breakthrough for Alzheimer’s.

Researchers have developed blood tests that can detect Alzheimer’s before symptoms appear — progress that now exceeds what Medicare can cover under current law. That legal barrier has real consequences: fewer than 10% of people living with mild cognitive impairment ever receive a diagnosis, meaning most aren’t identified early enough to benefit from today’s FDA-approved treatments. More than 9 in 10 Americans say they would want a simple test for Alzheimer’s.

The bipartisan Alzheimer’s Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267) clears that roadblock. The bill doesn't mandate coverage — it simply makes coverage possible through Medicare’s existing evidence-based process. Early detection gives individuals more time to begin treatment, plan ahead, enroll in clinical trials, and seek support when it matters most.

The Alzheimer’s Association and AIM are proud to work with bipartisan congressional champions to advance the ASAP Act. Join us in urging Congress to act.